Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2011-07-20
Original SEC Filing: Click here

---

Webplus: SVA/20110720/6-K/2_EX-99.1/000.htm SEC Original: v229007_ex99-1.htm
Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of

---

---

Webplus: SVA/20110720/6-K/3_EX-99.2/000.htm SEC Original: v229007_ex99-2.htm
Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase

---

---

Webplus: SVA/20110720/6-K/1/000.htm SEC Original: v229007_6k.htm
SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2011-07-20CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085